-+ 0.00%
-+ 0.00%
-+ 0.00%

MERCK’S KEYTRUDA QLEX™ (PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH) APPROVED IN JAPAN FOR SUBCUTANEOUS ADMINISTRATION FOR ALL KEYTRUDA® (PEMBROLIZUMAB) INDICATIONS APPROVED IN JAPAN

Reuters·09/21/2026 10:45:00

Please log in to view news